Advanced search
Publication Cover
Journal of Chemotherapy Volume 15, 2003 - Issue 6
Submit an article Journal homepage
62
Views
32
CrossRef citations to date
0
Altmetric
Original Experimental and Clinical Research

Diffusion of Oral and Intravenous 400 mg Once-Daily Moxifloxacin into Lung Tissue at Pharmacokinetic Steady-State

D. Breilh
,
J. Jougon
,
S. Djabarouti
,
J.B. Gordien
,
F. Xuereb
,
J.F. Velly
,
P. Arvis
,
V. Landreau
&
M.C. Saux
 show all
Pages 558-562 | Published online: 18 Jul 2013

REFERENCES

  • Eicher HG, Müller M. Drug distribution-the forgotten rel-ative of clinical pharmacokinetics. Clin Pharmacokinet 1998; 34: 95–99.
  • Hyatt JM, McKinnon PS, Zimmer GS, Schentag JJ. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Clin Pharmacokinet 1995; 28: 143–160.
  • Drusano GL, Craig W. Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respi-ratory tract infections. J Chemother 1997; 9 Suppl 3: 38–44.
  • Craig W. Pharmacodynamics of antimicrobial agents as a basis for determining dosage regimens. Eur J Clin Microb Infect Dis 1993;12 Suppl. 1: S6-S8.
  • Dawson SJ, Reeves DS. Therapeutic monitoring, the concentration-effect relationship and impact on the clinical efficacy of antibiotic agents. J Chemother 1997; 9 Suppl 1: 84–92.
  • Rotschafer JC, Zabinski RA, Walker KJ. Pharmacodynamic factors of antibiotic efficacy. Pharmacotherapy 1992; 12: 64S-70S.
  • Baldwin DR, Honeybourne D, Wise R. Pulmonary dis-position of antimicrobial agents: in vivo observations and clini-cal relevance. Antimicrob Agents Chemother 1992; 36: 1176–1180.
  • Lemoine T, Breilh D, Ducint D, Dubrez J, Jougon J, Velly JF, et al. Determination of moxifloxacin (BAY 12-8039) in plasma and lung tissue by high-performance liquid chro-matography with ultraviolet detection using a fully automated extraction method with a new polymeric cartridge. J Chrom B 2000; 742: 247–254.
  • Stass H, Kubitza D, Schüly U. Pharmacokinetics, safety and tolerability of moxifloxacin, a novel 8-methoxyfluoro-quinolone, after repeated oral administration. Clin Pharmacokinet 2001; 40 Suppl. 1: 1-9.
  • Stass H, Kubitza D. Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. J Antimicrob Chemother 1999; 43 Suppl. B: 83-90.
  • Ballow C, Letter' J, Agarwal V et al. Absolute bioavail-ability of moxifloxacin. Clin Ther 1999; 21: 513–22.
  • Nightingale CH. Moxifloxacin, a new antibiotic designed to treat community-acquire respiratory tract infec-tions: a review of microbiologic and pharmacokinetic-pharma-codynamic characteristics. Pharmacotherapy 2000; 20: 245–56.
  • Garcia-Rodriguez JA, Gomez-Garcia AC. The microbi-ology of moxifloxacin. Drugs Today 2000; 36: 215–227.
  • Boswell EJ, Andrews JM, Wise R, Dalhoff A. Bactericidal properties of moxifloxacin and post-antibiotic effect. J Antimicrob Chemother 1999; 43: 43–49.
  • Dalhoff A. Pharmacodynamics of fluoroquinolones. J Antimicrob Chemother 1999; 43 Suppl. B: 51-59.
  • Drusano GL. Pharmacology of antiinfective agents. In: Mendel GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases. 4th ed. New York: Churchill Livingstone; 1995: 225–233.
  • Schentag JJ, Nix DE, Forrest A. Pharmacodynamics of the fluoroquinolones. In Quinolone Antimicrobial Agents, 2nd ed (Hooper DC and Wolfson JS., eds), American Society for Microbiology, Washington DC. 1993: 259-271.
  • Honeybourne D. Antibiotic penetration in the respirato-ry tract and implications for the selection of antimicrobial ther-apy. Current opinion Pulm Med 1997; 3: 170–174.
  • Nix DE. Intrapulmonary concentrations of antimicrobial agents. Infect Dis Clin North Am 1998; 12: 631–646.
  • Wise R. A review of the clinical pharmacology of moxi-floxacin, a new 8-methoxyquinolone, and its potential relation to therapeutic efficacy. Clin Drug Invest 1999; 17: 365–87.
  • Andrews J, Honeybourne D, Jevous G, Wise R. Penetration of moxifloxacin into bronchial mucosa, epithelium lining fluid and alveolar macrophages following a single 400 mg dose. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego CA. 1998. Abstract A29.
  • Soman A, Honeybourne D, Andrews J, Jevons G, Wise R. Concentrations of moxifloxacin in serum and pul-monary compartments following a single 400mg oral dose in patients undergoing fibre-optic bronchoscopy. J Antimicrob Chemother. 1999; 44: 835–838.
  • Blondeau JM. Expanded activity and utility of the new fluoroquinolones: a review. Clin Ther 1999; 21: 3–40.
  • Blondeau JM. A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new “respiratory quinolones”. J Antimicrob Chemother 1999; 43 Suppl. B: 1-11.
  • Gehanno P, Darantière S, Dubreuil C, Chobaut JC, Bobin S, Pages JC et al. A prospective, multicentre study of moxifloxacin concentrations in the sinus mucosa tissue of patients undergoing elective surgery of the sinus. J Antimicrob Chemother 2002; 49: 821–826.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.